Alisa S Cosan1, Julietta U Schweiger2, Kai G Kahl3, Bettina Hamann4, Michael Deuschle5, Ulrich Schweiger1, Anna L Westermair1. 1. Klinik für Psychiatrie und Psychotherapie, Universität zu Lübeck, Lubeck, Germany. 2. LADR Geesthacht, Geesthacht, Germany. 3. Klinik für Psychiatrie, Sozialpsychiatrie und Psychotherapie, Medizinische Hochschule Hannover, Hannover, Germany. 4. Kerkhoff Klinik, Bad Nauheim, Germany. 5. Zentralinstitut für Seelische Gesundheit, Fakultät für Medizin Mannheim, Universität Heidelberg, Mannheim, Germany.
Abstract
INTRODUCTION: Depressive disorders are a common illness worldwide. Major depression is known as a significant predictor of the metabolic syndrome. However, the effects of depression on adipose tissue compartments are controversial. This meta-analysis aimed to evaluate the state of research on the relationship between patients with depression and adipose tissue compartments as compared to nondepressed individuals. METHODS: The PubMed database was searched for human studies that measured adipose tissue compartments such as visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT) and/or organ-specific adipose tissue measurements using dual-energy X-ray absorptiometry, magnetic resonance imaging or computed tomography scan and reported the means and a measure of variance separately for depressed individuals and healthy controls. Twelve articles were identified, including a total of 1,141 depressed and 2,545 nondepressed individuals. RESULTS: Major depressive disorder and self-reported depressive symptoms were associated with elevated visceral adipose tissue and elevated subcutaneous adipose tissue. Subanalyses for gender, age, method of adipose tissue measurement, and method of depression assessment showed elevated visceral adipose in depressed individuals. The results could be replicated when focussing on studies controlling for body mass index (BMI). Regarding other adipose tissue compartments, meta-analysis could not be carried out due to lack of studies. CONCLUSIONS: Depression is associated with enlarged visceral and subcutaneous adipose tissue. Further, especially longitudinal, research is needed to identify the mechanism through which depressive disorders contribute to visceral adiposity.
INTRODUCTION:Depressive disorders are a common illness worldwide. Major depression is known as a significant predictor of the metabolic syndrome. However, the effects of depression on adipose tissue compartments are controversial. This meta-analysis aimed to evaluate the state of research on the relationship between patients with depression and adipose tissue compartments as compared to nondepressed individuals. METHODS: The PubMed database was searched for human studies that measured adipose tissue compartments such as visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT) and/or organ-specific adipose tissue measurements using dual-energy X-ray absorptiometry, magnetic resonance imaging or computed tomography scan and reported the means and a measure of variance separately for depressed individuals and healthy controls. Twelve articles were identified, including a total of 1,141 depressed and 2,545 nondepressed individuals. RESULTS: Major depressive disorder and self-reported depressive symptoms were associated with elevated visceral adipose tissue and elevated subcutaneous adipose tissue. Subanalyses for gender, age, method of adipose tissue measurement, and method of depression assessment showed elevated visceral adipose in depressed individuals. The results could be replicated when focussing on studies controlling for body mass index (BMI). Regarding other adipose tissue compartments, meta-analysis could not be carried out due to lack of studies. CONCLUSIONS:Depression is associated with enlarged visceral and subcutaneous adipose tissue. Further, especially longitudinal, research is needed to identify the mechanism through which depressive disorders contribute to visceral adiposity.
Authors: Nicole Vogelzangs; Stephen B Kritchevsky; Aartjan T F Beekman; Gretchen A Brenes; Anne B Newman; Suzanne Satterfield; Kristine Yaffe; Tamara B Harris; Brenda W J H Penninx Journal: J Clin Psychiatry Date: 2009-12-15 Impact factor: 4.384
Authors: Oskar Ragnarsson; Camilla A M Glad; Ragnhildur Bergthorsdottir; Erik G Almqvist; Eva Ekerstad; Håkan Widell; Bo Wängberg; Gudmundur Johannsson Journal: Eur J Endocrinol Date: 2015-01 Impact factor: 6.664
Authors: K G Kahl; J Herrmann; B Stubbs; T H C Krüger; J Cordes; M Deuschle; U Schweiger; K Hüper; S Helm; A Birkenstock; D Hartung Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2016-08-13 Impact factor: 5.067
Authors: Moffat J Nyirenda; Roderick Carter; Justin I Tang; Annick de Vries; Christina Schlumbohm; Stephen G Hillier; Frank Streit; Michael Oellerich; Victor W Armstrong; Eberhard Fuchs; Jonathan R Seckl Journal: Diabetes Date: 2009-08-31 Impact factor: 9.461
Authors: Alisa S Cosan; Julietta U Schweiger; Kai G Kahl; Bettina Hamann; Michael Deuschle; Ulrich Schweiger; Anna L Westermair Journal: Brain Behav Date: 2020-11-05 Impact factor: 2.708
Authors: Claudia von Zimmermann; Lena Brückner; Christiane Mühle; Christian Weinland; Johannes Kornhuber; Bernd Lenz Journal: Front Psychiatry Date: 2022-07-19 Impact factor: 5.435
Authors: Randa K Saad; Malak Ghezzawi; Renee Horanieh; Assem M Khamis; Katherine H Saunders; John A Batsis; Marlene Chakhtoura Journal: Front Endocrinol (Lausanne) Date: 2022-08-22 Impact factor: 6.055
Authors: Alisa S Cosan; Julietta U Schweiger; Kai G Kahl; Bettina Hamann; Michael Deuschle; Ulrich Schweiger; Anna L Westermair Journal: Brain Behav Date: 2020-11-05 Impact factor: 2.708